352 related articles for article (PubMed ID: 27840112)
1. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.
de Wilde AH; Falzarano D; Zevenhoven-Dobbe JC; Beugeling C; Fett C; Martellaro C; Posthuma CC; Feldmann H; Perlman S; Snijder EJ
Virus Res; 2017 Jan; 228():7-13. PubMed ID: 27840112
[TBL] [Abstract][Full Text] [Related]
2. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
de Wilde AH; Jochmans D; Posthuma CC; Zevenhoven-Dobbe JC; van Nieuwkoop S; Bestebroer TM; van den Hoogen BG; Neyts J; Snijder EJ
Antimicrob Agents Chemother; 2014 Aug; 58(8):4875-84. PubMed ID: 24841269
[TBL] [Abstract][Full Text] [Related]
3. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
4. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
5. A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses.
Ahn DG; Yoon GY; Lee S; Ku KB; Kim C; Kim KD; Kwon YC; Kim GW; Kim BT; Kim SJ
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452503
[TBL] [Abstract][Full Text] [Related]
6. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses.
Adedeji AO; Singh K; Kassim A; Coleman CM; Elliott R; Weiss SR; Frieman MB; Sarafianos SG
Antimicrob Agents Chemother; 2014 Aug; 58(8):4894-8. PubMed ID: 24841268
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Winslow S; Hoopes J; Li JK; Lee J; Carson DA; Cottam HB; Sidwell RW
Antiviral Res; 2006 Aug; 71(1):53-63. PubMed ID: 16621037
[TBL] [Abstract][Full Text] [Related]
9. Animal models for SARS and MERS coronaviruses.
Gretebeck LM; Subbarao K
Curr Opin Virol; 2015 Aug; 13():123-9. PubMed ID: 26184451
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
11. Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus
Sauerhering L; Kupke A; Meier L; Dietzel E; Hoppe J; Gruber AD; Gattenloehner S; Witte B; Fink L; Hofmann N; Zimmermann T; Goesmann A; Nist A; Stiewe T; Becker S; Herold S; Peteranderl C
Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32616594
[TBL] [Abstract][Full Text] [Related]
12. What are our pharmacotherapeutic options for MERS-CoV?
Al-Tawfiq JA; Memish ZA
Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
Strayer DR; Dickey R; Carter WA
Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238
[TBL] [Abstract][Full Text] [Related]
15. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta 1a and SARS coronavirus replication.
Hensley LE; Fritz LE; Jahrling PB; Karp CL; Huggins JW; Geisbert TW
Emerg Infect Dis; 2004 Feb; 10(2):317-9. PubMed ID: 15030704
[TBL] [Abstract][Full Text] [Related]
17. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
18. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
Tian L; Liu W; Sun L
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.
Peters HL; Jochmans D; de Wilde AH; Posthuma CC; Snijder EJ; Neyts J; Seley-Radtke KL
Bioorg Med Chem Lett; 2015 Aug; 25(15):2923-6. PubMed ID: 26048809
[TBL] [Abstract][Full Text] [Related]
20. Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.
Millet JK; Séron K; Labitt RN; Danneels A; Palmer KE; Whittaker GR; Dubuisson J; Belouzard S
Antiviral Res; 2016 Sep; 133():1-8. PubMed ID: 27424494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
